Logo of Noxopharm (ASX:NOX)Latest Noxopharm (ASX:NOX) News

Page 4
Page 4 of 4

Noxopharm Advances SOF-SKN Trial Amid Rising Losses and $2.6M Funding Boost

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.
Ada Torres
29 Aug 2025

Noxopharm Advances HERACLES Trial, Clears Third SOF-SKN™ Dose Safely

Noxopharm has successfully completed the third dosing phase of its HERACLES trial for SOF-SKN™, confirming safety and moving forward to the highest dose cohort in this pioneering autoimmune drug study.
Ada Torres
25 Aug 2025

Noxopharm Advances SOF-SKN™ Trial with Safe Second Dose Completion

Noxopharm Limited has successfully completed the second dose cohort in its HERACLES Phase 1 trial for SOF-SKN™, confirming safety and tolerability and moving forward to a higher dose. This progress marks a key step in developing a novel autoimmune disease treatment.
Ada Torres
11 Aug 2025

Noxopharm and Tezcat Biosciences Unlock New Potential for Sofra™ Drug Delivery

Noxopharm’s Sofra™ technology shows promising results in collaboration with US biotech Tezcat Biosciences, advancing targeted drug delivery for cancer and inflammatory diseases.
Ada Torres
5 Aug 2025

Noxopharm Launches HERACLES Trial, Expands Sofra Collaborations Amid Funding Push

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.
Ada Torres
30 July 2025

Noxopharm Advances HERACLES Trial with Safe Low-Dose SOF-SKN Completion

Noxopharm Limited has successfully completed the first low-dose cohort in its HERACLES clinical trial for SOF-SKN™, clearing the way for higher dose testing in autoimmune disease treatment.
Ada Torres
28 July 2025

Noxopharm’s Sofra™ Platform Gains Strong Validation from BioRay Collaboration

Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.
Ada Torres
11 June 2025

Noxopharm Launches First Human Trial for SOF-SKN™ Targeting Lupus

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.
Ada Torres
29 May 2025

Noxopharm Secures $2.5M Boost to Propel HERACLES Trial and R&D

Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.
Ada Torres
20 May 2025

Noxopharm Advances SOF-SKN™ to Clinical Trials Amid Growing Global Collaborations

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.
Ada Torres
30 Apr 2025

Noxopharm’s SOF-SKN™ Clears Crucial Safety Hurdles Ahead of HERACLES Trial

Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.
Ada Torres
4 Feb 2025

Noxopharm Secures New MTAs and Boosts Cash with $2.34M R&D Rebate

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.
Ada Torres
29 Jan 2025